Mercury Laboratories Ltd.

850.15 -24.85 ▼-2.8%

06 May 2024, 04:01:00 PM
Volume: 227

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.mercurylabs.com
Market Cap 102.08 Cr.
Enterprise Value(EV) 101.87 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 34.26 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 24.83 Trailing Twelve Months Ending 2023-12
Industry PE 42.26 Trailing Twelve Months Ending 2023-12
Book Value / Share 407.78 Trailing Twelve Months Ending 2023-12
Price to Book Value 2.09 Calculated using Price: 850.70
Dividend Yield 0.41 Period Ending 2023-03
No. of Shares Subscribed 0.12 Cr. 1,200,000 Shares
FaceValue 10
About Mercury Laboratories Ltd.
The company is engaged in manufacturing of pharmaceutical products. It is mainly dedicated to Mother and child care products.

Mercury Laboratories Ltd. Delivery

Delivered Qty
Traded Qty

Mercury Laboratories Ltd. Performance

1 Day
-2.84%
1 Week
-4.90%
1 Month
-3.94%
3 Month
-24.77%
6 Month
+6.94%
1 Year
+43.79%
2 Year
+66.70%
5 Year
+193.16%
10 Year

Mercury Laboratories Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 19.75 19.62 11.67 7.92 10.26 10.59 15.5 9.23 12.98
Return on Capital Employed (%) 21.32 21.58 18.93 9.89 13.77 13.25 20.56 12.26 16.29
Return on Assets (%) 8.01 8.81 5.54 3.92 5.2 5.68 8.77 5.57 8.58

Mercury Laboratories Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 18 22 24 26 29 32 37 40 46 48
Non Curr. Liab. 4 4 10 12 11 9 10 6 6 6
Curr. Liab. 21 20 17 13 17 15 19 16 16 21
Minority Int.
Equity & Liab. 43 47 51 52 57 56 65 62 68 75
Non Curr. Assets 20 19 20 22 25 25 28 27 26 27
Curr. Assets 23 28 31 30 32 32 38 35 42 48
Misc. Exp. not W/O
Total Assets 43 47 51 52 57 56 65 62 68 75

Mercury Laboratories Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 41 48 48 52 56 57 69 58 75 78
Other Income 1 1 0 0 1 1 1 1 2 1
Total Income 42 48 48 52 57 58 69 59 77 79
Total Expenditure -35 -41 -41 -47 -50 -51 -59 -51 -67 -70
PBIDT 7 7 7 5 7 7 10 8 10 9
Interest -1 -1 -1 -1 -1 -1 -1 0 0 0
Depreciation -1 -1 -1 -1 -2 -2 -2 -2 -2 -3
Taxation -1 -1 -2 0 -1 -1 -3 -1 -2 -1
Exceptional Items 0 0 0
PAT 3 4 3 2 3 3 5 4 6 4
Adjusted EPS 28 33 23 17 24 27 44 30 46 34

Mercury Laboratories Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 3 3 0 2 5 5 5 8 5 2
Cash Fr. Inv. -2 -2 0 -2 -4 -5 -1 -5 -2 -1
Cash Fr. Finan. -1 -2 0 0 1 -3 -3 -1 -1 -1
Net Change 0 0 0 0 2 -2 1 2 2 0
Cash & Cash Eqvt 1 1 1 1 4 1 3 5 7 7

Mercury Laboratories Ltd. Shareholding Pattern

9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 73.66 73.66 73.66 73.66 73.66 73.66 73.66 73.66 73.66
Public 26.34 26.34 26.34 26.34 26.34 26.34 26.34 26.34 26.34
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Mercury Laboratories Ltd. Announcements

Tue, 30 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation for Loss of Share Certificate_Manish N Shah
Mon, 29 Apr 2024
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Company Mercury Laboratories Ltd
2 CIN NO. L74239MH1982PLC026341
3 Report filed for FY 2023-2024
Details of the Current block (all figures in Rs crore):
4 2 - year block period (Specify financial years)* 2023-24 24-25
5 Incremental borrowing done in FY (T)(a) 0.00
6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
7 Actual borrowing done through debt securities in FY (T)(c) 0.00
8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
8Quantum of (d) which has been met from (c)(e)* 0
9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)2022-23 23-24
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



Name of the Company Secretary :-Krishna Shah
Designation :-Company Secretary and Compliance Officer
Name of the Chief Financial Officer :- Ashish Vasavada
Designation : -Chief Financial Officer

Date: 29/04/2024

Mon, 29 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyMercury Laboratories Ltd
2CIN NO.L74239MH1982PLC026341
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 3.04
4Highest Credit Rating during the previous FY BB+stable
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD.
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Krishna Shah
Designation: Company Secretary and Compliance Officer
EmailId: secretarial@mercurylabs.com
Name of the Chief Financial Officer: Ashish Vasavada
Designation: Chief Financial Officer
EmailId: cfo@mercurylabs.com

Date: 29/04/2024

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Mercury Laboratories Ltd. Technical Scans

Mon, 06 May 2024
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
High Decrease in 3 Months High Decrease in 3 Months
High Increase in 1 Year High Increase in 1 Year

Mercury Laboratories Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 367,026.27 1,529.55 +1.4%
Cipla Ltd. 114,924.60 1,423.40 -0.1%
Divi's Laboratories Ltd. 105,128.21 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. 105,108.85 6,293.45 -0.9%
Zydus Lifesciences Ltd. 102,736.49 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. 91,906.55 2,720.45 -0.4%
Mankind Pharma Ltd. 91,490.39 2,286.05 -1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.21 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-12 30.99 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 76.02 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.10 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.55 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 61.52 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-12 52.97 2,286.05 -1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.88 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-12 4.44 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 8.07 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.91 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.45 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.85 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-12 10.30 2,286.05 -1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 0.02 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,286.05 -1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,286.05 -1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,286.05 -1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,286.05 -1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,286.05 -1.2%

Mercury Laboratories Ltd. FAQ's

What is Mercury Laboratories share price?

Can I buy Mercury Laboratories shares now?

What is the Dividend Yield of Mercury Laboratories?

What is the Market Cap of Mercury Laboratories?

What are the key metrics to analyse Mercury Laboratories?

What is the 52 Week High and Low of Mercury Laboratories?

What is the trend of Mercury Laboratories share price?